EnVivo Pharmaceuticals, Inc. Names Christopher L. Burnley Chief Business Officer  
4/19/2012 10:06:00 AM

WATERTOWN, Mass.--(BUSINESS WIRE)--EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today announced that Christopher L. Burnley has been appointed chief business officer. Mr. Burnley brings 25 years of broad industry experience focused on business operations, finance, strategy development and corporate development. In his new role, he will be responsible for shaping EnVivo’s long-term corporate strategy and executing its business development plans.